Synergistic effects of antimicrobial peptides and antibiotics against clostridium difficile

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 5719-5725

  Nuding, Sabine ^a,b   Frasch, Tina ^c   Schaller, Martin ^b   Stange, Eduard F ^d   Zabel, Lutz T ^c  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Alb Fils Hospital   (Germany)

^d ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL PEPTIDE HBD1; ANTIMICROBIAL PEPTIDE HBD2; ANTIMICROBIAL PEPTIDE HBD3; ANTIMICROBIAL PEPTIDE HD5; ANTIMICROBIAL PEPTIDE HNP1; BACTERIAL TOXIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; PEPTIDE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DRUG INHIBITION; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; DRUG EFFECTS; DRUG POTENTIATION; MICROBIAL SENSITIVITY TEST; PEPTOCLOSTRIDIUM DIFFICILE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DRUG SYNERGISM; FLOW CYTOMETRY; MICROBIAL SENSITIVITY TESTS; PEPTIDES;

EID: 84907266307     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02542-14     Document Type: Article

References (20)

1. Venugopal AA, Johnson S. 2012. Current state of Clostridium difficile treatment options. Clin. Infect. Dis. 55 (Suppl 2):S71-S76. http://dx.doi.org/10.1093/cid/cis355.
2. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, OPT-80-003 Clinical Study Group. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 64:422-431. http://dx.doi.org/10.1056/NEJMoa0910812.
3. Ganz T. 2003. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3:710-720. http://dx.doi.org/10.1038/nri1180.
4. Klotman ME, Chang TL. 2006. Defensins in innate antiviral immunity. Nat. Rev. Immunol. 6:447-456. http://dx.doi.org/10.1038/nri1860.
5. Ouellette AJ. 2011. Paneth cell a-defensins in enteric innate immunity. Cell. Mol. Life Sci. 68:2215-2229. http://dx.doi.org/10.1007/s00018-011-0714-6.
6. Wehkamp J, Harder J, Weichenthal M, Mueller O, Herrlinger KR, Fellermann K, Schroeder JM, Stange EF. 2003. Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis. 9:215-223. http://dx.doi.org/10.1097/00054725-200307000-00001.
7. Fahlgren A, Hammarström S, Danielsson A, Hammarstrom ML. 2004. Beta-defensin-3 and -4 in intestinal epithelial cells display increased mRNAexpression in ulcerative colitis. Clin. Exp. Immunol. 137:379-385. http://dx.doi.org/10.1111/j.1365-2249.2004.02543.x.
8. Kai-Larsen Y, Agerberth B. 2008. The role of the multifunctional peptide LL-37 in host defense. Front. Biosci. 13:3760-3767.
9. Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-250. http://dx.doi.org/10.1038/nrmicro1098.
10. McQuade R, Roxas B, Viswanathan VK, Vedantam G. 2012. Clostridium difficile clinical isolates exhibit variable susceptibility and proteome alterations upon exposure to mammalian cationic antimicrobial peptides. Anaerobe 18:614-620. http://dx.doi.org/10.1016/j.anaerobe .2012.09.004.
11. Giesemann T, Guttenberg G, Aktories K. 2008. Human alpha-defensins inhibit Clostridium difficile toxin B. Gastroenterology 134:2049-2058. http://dx.doi.org/10.1053/j.gastro.2008.03.008.
12. Nuding S, Zabel LT, Enders C, Porter E, Fellermann K, Wehkamp J, Mueller HA, Stange EF. 2009. Antibacterial activity of human defensins on anaerobic intestinal bacterial species: a major role of HBD-3. Microbes Infect. 11:384-393. http://dx.doi.org/10.1016/j.micinf.2009.01.001.
13. Schroeder BO, Wu Z, Nuding S, Groscurth S, Marcinowski M, Beisner J, Buchner J, Schaller M, Stange EF, Wehkamp J. 2011. Reduction of disulfide bonds unmasks potent antimicrobial activity of human-defensin 1. Nature 469:419-423. http://dx.doi.org/10.1038/nature09674.
14. Nuding S, Zabel LT. 2013. Detection, identification, and susceptibility testing of bacteria by flow cytometry. J. Bacteriol. Parasitol. S5:e00l. http://dx.doi.org/10.4172/2155-9597.
15. Baines SD, Saxton K, Freeman J, Wilcox MH. 2006. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J. Antimicrob. Chemother. 58:1062-1065. http://dx.doi.org/10.1093/jac/dkl364.
16. Onderdonk AB, Lowe BR, Bartlett JG. 1979. Effect of environmental stress on Clostridium difficile toxin levels during continuous cultivation. Appl. Environ. Microbiol. 38:637-641.
17. Aldape MJ, Packham AE, Nute DW, Bryant AE, Stevens DL. 2013. Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile. J. Med. Microbiol. 62:741-747. http://dx.doi.org/10.1099/jmm.0.056218-0.
18. Shan J, Patel KV, Hickenbotham PT, Nale JY, Hargreaves KR, Clokie MR. 2012. Prophage carriage and diversity within clinically relevant strains of Clostridium difficile. Appl. Environ. Microbiol. 78:6027-6034. http://dx.doi.org/10.1128/AEM.01311-12.
19. Goh S, Chang BJ, Riley TV. 2005. Effect of phage infection on toxin production by Clostridium difficile. J. Med. Microbiol. 54:129-135. http://dx.doi.org/10.1099/jmm.0.45821-0.
20. Sekulovic O, Meessen-Pinard M, Fortier L-C. 2011. Prophagestimulated toxin production in Clostridium difficile NAP1/O27 lysogens. J. Bacteriol. 193:2726-2734. http://dx.doi.org/10.1128/JB.00787-10.